Patents Examined by Christopher R Stone
  • Patent number: 10292974
    Abstract: The present invention provides a prophylactic or therapeutic agent for giant cell tumors occurring in a bone and soft tissue or for chondrosarcoma, which comprises a non-steroidal anti-inflammatory agent or thiazolidine derivative as an active ingredient, and the like.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: May 21, 2019
    Assignee: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Akihiko Takeuchi, Hiroyuki Tsuchiya
  • Patent number: 10278955
    Abstract: One embodiment is a method of treating cancer. The method includes administering a therapeutically effective amount of a compound to a patient.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: May 7, 2019
    Assignee: Macau University of Science and Technology
    Inventors: Xiao Jun Yao, Lai Han Elaine Leung, Liang Liu, Qian Qian Wang, Jia Hui Xu, Ying Li
  • Patent number: 10272086
    Abstract: Methods for treating androgen receptor related diseases and suppressing androgen receptor related function by administering an effective amount of minoxidil are provided. Methods for treating or prophylactically treating acne by administering an effective amount of minoxidil are also provided. An anti-acne medication is optionally administered to treat or prophylactically treat acne.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: April 30, 2019
    Assignees: Chang Gung Memorial Hospital, Linkou
    Inventor: Cheng-Lung Hsu
  • Patent number: 10238614
    Abstract: This disclosure relates to the use of EACA (6-aminohexanoic acid) as an antifibrinolytic for the prevention of thrombocytopenic bleeds. In certain embodiment, the disclosure relates to methods of preventing bleeding in patients with thrombocytopenia resulting from hematological malignancies by administering 6-aminohexanoic acid, salts, or prodrugs thereof prophylactically to a subject in need thereof. In certain embodiments, subjects with stable chronic thrombocytopenia previously managed with platelet transfusion represent a selected group of patients that benefit from prophylaxis.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: March 26, 2019
    Assignee: Emory University
    Inventors: Hanna Jean Khoury, Ana Antun
  • Patent number: 10207985
    Abstract: Compounds of the formula in which the substituents are as defined in claim 1, are suitable for use as nematicides.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: February 19, 2019
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Regis Jean Georges Mondiere, Olivier Loiseleur, Andre Jeanguenat, Anthony Cornelius O'Sulivan
  • Patent number: 10202348
    Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: February 12, 2019
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Thomas A. Jordan, John E. Dowling, John Clifford Chabala
  • Patent number: 10189843
    Abstract: The present invention provides a compound of formula (1), wherein R1, R2, R3, R4a, R4b, R5a and R5b are as defined in the description, which has an autotaxin inhibitory activity, a pharmaceutical composition comprising the compound as an active ingredient, and a method of prevention or treatment of a disease involving autotaxin, which is characterized by administering the compound.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: January 29, 2019
    Assignees: THE UNIVERSITY OF TOKYO, TOHOKU UNIVERSITY, SHIONOGI & CO., LTD.
    Inventors: Tetsuo Nagano, Takayoshi Okabe, Hirotatsu Kojima, Mitsuyasu Kawaguchi, Osamu Nureki, Ryuichiro Ishitani, Hiroshi Nishimasu, Junken Aoki, Chiaki Fujikoshi, Manabu Katou, Masahide Odan, Nobuyuki Tanaka, Yusuke Tateno, Junji Yamane
  • Patent number: 10172836
    Abstract: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: January 8, 2019
    Assignee: PTC Therapeutics, Inc.
    Inventors: Samit Hirawat, Langdon Miller
  • Patent number: 10125094
    Abstract: Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, salts, hydrates and solvates thereof, wherein R1, R2, R3 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: November 13, 2018
    Assignee: Janssen Sciences Ireland UC
    Inventors: Koen Vandyck, Stefaan Julien Last, Pierre Jean-Marie Bernard Raboisson
  • Patent number: 10077277
    Abstract: This application relates to derivatives of Formula I: and pharmaceutically acceptable salts thereof, which are inhibitors of PI3K, and compositions and methods of treatment related thereto.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: September 18, 2018
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Andrew P. Combs
  • Patent number: 10064844
    Abstract: The present invention relates to low-dose pharmaceutical compositions comprising the aromatase inhibitor 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, as the active ingredient in a suitable carrier. The present invention also relates to a process for their preparation and to their use as medicaments.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: September 4, 2018
    Assignee: MEREO BIOPHARMA 2 LIMITED
    Inventors: Ann Taylor, Lloyd B. Klickstein, Jeewan Thakur
  • Patent number: 10010547
    Abstract: This invention relates to compounds that inhibit or modulate the activity of Chk-1 kinase. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: July 3, 2018
    Assignee: Cascadian Therapeutics, Inc.
    Inventors: Robert George Boyle, David Winter Walker, Richard Justin Boyce, Scott Peterson, Francine Farouz, Cong Hung Vo
  • Patent number: 10004684
    Abstract: The invention relates to pharmaceutical formulations for use in the administration of lipophilic medicaments via mucosal surfaces. In particular the invention provides pharmaceutical formulations for use in administration of a lipophilic medicament via a mucosal surface which upon hydration form an emulsion containing the lipophilic medicament which is capable of adhering to a mucosal surface and allowing controlled release of the medicament. The invention further provides pharmaceutical formulations which contain, as active ingredients, specific combinations of cannabinoids in pre-defined ratios.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: June 26, 2018
    Assignee: GW Pharma Limited
    Inventors: Brian Whittle, Geoffrey Guy
  • Patent number: 9975896
    Abstract: The present invention provides novel compounds of any one of Formulae (I) to (IV), and pharmaceutically compositions thereof. Compounds of any one of Formulae (I) to (IV) are believed to be inhibitors of bromodomain-containing proteins (e.g., bromo and extra terminal proteins (BETs)). Also provided are methods, uses, and kits using the inventive compounds and pharmaceutical compositions for inhibiting the activity of the bromodomain-containing proteins and for treating and/or preventing in a subject in need thereof diseases associated with bromodomain-containing proteins, such as proliferative diseases.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: May 22, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., University of Massachusetts
    Inventors: Jason J. Marineau, James E. Bradner, Wei Zhang, Jun Qi, Michael R. McKeown, Harry Hongning Fu, Shuai Liu
  • Patent number: 9957173
    Abstract: The present invention relates to water treatment. In one embodiment there is provided a method of treating an aqueous system to inhibit growth of one or more micro-organisms therein and/or to reduce the number of live micro-organisms therein. The method comprises adding treatment agents to said aqueous system and wherein said treatment agents comprise: (a) a phosphonium compound; and (b) an nitro compound.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: May 1, 2018
    Assignee: BWA Water Additives UK Limited
    Inventors: Jeffrey Frank Kramer, Christy Colleen Wentworth
  • Patent number: 9951087
    Abstract: The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment disorders.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: April 24, 2018
    Assignee: Fibrotech Therapeutics PTY LTD
    Inventors: Spencer John Williams, Steven Zammit, Darren James Kelly
  • Patent number: 9924718
    Abstract: Control and repellency of biting flies, house flies, ticks, ants, fleas, biting midges, cockroaches, spiders and stink bugs is obtained by contact of the insects with at least one of the compounds of the structure (I).
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: March 27, 2018
    Assignee: Bedoukian Research, Inc.
    Inventor: Robert H. Bedoukian
  • Patent number: 9925189
    Abstract: Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: March 27, 2018
    Assignee: CYMABAY THERAPEUTICS, INC.
    Inventors: Xin Chen, Peng Cheng, L. Edward Clemens, Jeffrey D. Johnson, Jingyuan Ma, Alison Murphy, Imad Nashashibi, Christopher J. Rabbat, Jiangao Song, Maria E. Wilson, Yan Zhu, Zuchun Zhao
  • Patent number: 9896419
    Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: February 20, 2018
    Assignee: ALDEYRA THERAPEUTICS, INC.
    Inventors: Thomas A. Jordan, John E. Dowling, John Clifford Chabala
  • Patent number: 9895324
    Abstract: Halogenated diarylacetylenes, e.g., diarylacetylenes having at least one halo substituent in one aryl ring and an amine in the opposing aryl ring, can inhibit the proliferation of LS174T colon cancer cells through the inhibition of c-myc and induction of the cyclin-dependent kinase inhibitor-1 (i.e., p21(Wif1/Cip1)). Such compounds are useful as antineoplastic agents.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: February 20, 2018
    Assignee: University of Kentucky Research Foundation
    Inventors: Vitaliy M. Sviripa, Wen Zhang, Chunming Liu, David Watt